IP Library Granted Patent US 9,709,553
Granted Patent B2
US 9,709,553 · App. 12/990,874 · Granted Jul 18, 2017

Treating myelin diseases with optimized cell preparations

Inventors: Steven Goldman (Webster, NY); Fraser J. Sim (Buffalo, NY)
Assignee: University of Rochester
G01N33/5058C12N5/0622C12N5/0623A61K35/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,709,553
App. No.
12/990,874
Granted
Jul 18, 2017
Kind
B2
Abstract

The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.

Claims (15)

1. A method of isolating a population of human oligodendrocyte-biased glial progenitor cells, comprising the steps of:

(a) providing a population of human neural cells or neural precursor cells and

(b) recovering a population of A2B5+ and PSA-NCAM− human oligodendrocyte-biased glial progenitor cells from the provided population of human neural cells or neural precursor cells using only an agent that selectively binds to the CD140a ectodomain epitope of human PDGFαR, wherein the recovered population of cells has a higher percentage of said human oligodendrocyte-biased glial progenitor cells than when said recovering is carried out using antibodies directed against A2B5 and PSA-NCAM.

2. The method of claim 1 , wherein the recovering step is performed by FACS or magnetic sorting.

3. The method of claim 1 , wherein the agent is an antibody.

4. The method of claim 1 , wherein the recovered human oligodendrocyte-biased glial progenitor cells are immortalized.

5. The method of claim 4 , wherein the recovered human oligodendrocyte-biased glial progenitor cells express an exogenous nucleic acid encoding a human telomeric extension reverse transcriptase.

6. The method of claim 1 , wherein the provided population is derived from human neural tissue.

7. The method of claim 1 , wherein the provided population is derived from human multipotent or pluripotent stem cells.

8. The method of claim 7 , wherein the human pluripotent stem cells are induced human pluripotent stem cells.

9. The method of claim 1 , wherein the provided population is derived from human fetal cells.

10. The method of claim 1 , wherein the provided population is derived from human non-fetal cells.

11. The method of claim 1 further comprising:

culturing the recovered human oligodendrocyte-biased glial progenitor cells under conditions effective to form human oligodendrocytes.

12. The method of claim 1 , further comprising: culturing the recovered human oligodendrocyte-biased glial progenitor cells under conditions effective to form human astrocytes.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 23, 2013
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031076/0073 →
CONFIRMATORY LICENSE Recorded Oct 22, 2012
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029165/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2010
From: GOLDMAN, STEVEN; SIM, FRASER J.
To: UNIVERSITY OF ROCHESTER
Reel/Frame 025354/0733 →
Continuity (2)
Provisional Application 61051557 · May 8, 2008
Related Publication 20110059055A1 · Mar 10, 2011